RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Aandelen Lijst・Lonza Group AG

Lonza Group AG

Gesloten

SectorGezondheidszorg

493.4 3.09

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

478.65

Max

494.2

Belangrijke statistieken
By Trading Economics
Inkomsten	57M 483M
Verkoop	-621M 3B
K/W Sectorgemiddelde	37.585 67.147
Dividendrendement	1.04
Winstmarge	16.345
Werknemers	20,000
EBITDA	-181M 822M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+37.73% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	1.04% 2.36%
Volgende Winsten	22 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-4.6B 34B
Vorige openingsprijs	490.31
Vorige sluitingsprijs	493.4

Nieuwssentiment

By Acuity

14%

86%

24 / 347 Rangschikking in Healthcare

Lonza Group AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2026, 17:44 UTC

Acquisities, Fusies, Overnames

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

28 jan 2026, 06:15 UTC

Winsten

Lonza Sales Grow on New Contract Momentum

23 jul 2025, 08:30 UTC

Winsten

Belangrijke Marktbewegers

Lonza Shares Rise After Outlook Lift for Core Business

9 mrt 2026, 10:34 UTC

Marktinformatie

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

6 mrt 2026, 17:12 UTC

Acquisities, Fusies, Overnames

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

6 mrt 2026, 17:10 UTC

Acquisities, Fusies, Overnames

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

6 mrt 2026, 17:09 UTC

Acquisities, Fusies, Overnames

Lonza to Retain 40% Stake in CHI

6 mrt 2026, 17:08 UTC

Acquisities, Fusies, Overnames

Lonza Will Receive Upfront Proceeds of CHF1.7B

6 mrt 2026, 17:07 UTC

Acquisities, Fusies, Overnames

Lonza: Transaction Expected to Close in 2H

6 mrt 2026, 17:07 UTC

Acquisities, Fusies, Overnames

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

6 mrt 2026, 17:06 UTC

Acquisities, Fusies, Overnames

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

28 jan 2026, 12:04 UTC

Marktinformatie

Winsten

Lonza Results Show a Company in Good Shape -- Market Talk

28 jan 2026, 05:35 UTC

Winsten

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

28 jan 2026, 05:34 UTC

Winsten

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

28 jan 2026, 05:33 UTC

Winsten

Lonza Issues 2026 View

28 jan 2026, 05:32 UTC

Winsten

Lonza 2025 Core Ebitda Margin 31.6%

28 jan 2026, 05:32 UTC

Winsten

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

28 jan 2026, 05:32 UTC

Winsten

Lonza 2025 Core Ebitda CHF2.06B

28 jan 2026, 05:30 UTC

Winsten

Analysts Saw Lonza 2025 Sales at CHF7.54B

28 jan 2026, 05:30 UTC

Winsten

Lonza 2025 Sales CHF6.53B

27 okt 2025, 08:24 UTC

Marktinformatie

Lonza on Track to Meet Long-Term Goals -- Market Talk

23 okt 2025, 10:53 UTC

Marktinformatie

Winsten

Lonza Set to Recover as Contracts Flow in -- Market Talk

23 jul 2025, 08:00 UTC

Marktinformatie

Winsten

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 jul 2025, 04:44 UTC

Winsten

Lonza 1H Sales Grew 19% at Constant Currency

23 jul 2025, 04:43 UTC

Winsten

Lonza 1H Core Ebitda Margin 29.6%

23 jul 2025, 04:43 UTC

Winsten

Lonza: Margins Will Be Only Minimally Affected

23 jul 2025, 04:42 UTC

Winsten

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 jul 2025, 04:42 UTC

Winsten

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 jul 2025, 04:38 UTC

Winsten

Lonza 1H Net Pft CHF426M

23 jul 2025, 04:37 UTC

Winsten

Lonza Backs 2025 View for CHI Business

Peer Vergelijking

Prijswijziging

Lonza Group AG Prognose

Koersdoel

By TipRanks

37.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 660 CHF 37.73%

Hoogste 670 CHF

Laagste 630 CHF

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lonza Group AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Lonza Group AG - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

24 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.